BRVE
Braveheart Bio Inc. · NASDAQ
- Market cap
- $1.67B
- Shares out
- 89.9M
Braveheart Bio Inc. (BRVE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for BRVE, including 4 13D/G filings, 3 SEC filings and 2 press releases and news items. The most recent was published Nov 16, 2026.
BRVE rankings
News · 26 weeks10+100%
2026-05-242026-11-15
Mix1090d
- 13D/G4(40%)
- SEC Filings3(30%)
- Other2(20%)
- Earnings1(10%)
Activity · 52 weeks105 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
10 items- 13D/GSEC Form SCHEDULE 13G filed by Braveheart Bio Inc.SCHEDULE 13G - Braveheart Bio, Inc. (0002131524) (Subject)
- 13D/GSEC Form SCHEDULE 13G filed by Braveheart Bio Inc.SCHEDULE 13G - Braveheart Bio, Inc. (0002131524) (Subject)
- SECSEC Form 10-Q filed by Braveheart Bio Inc.10-Q - Braveheart Bio, Inc. (0002131524) (Filer)
- SECBraveheart Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Braveheart Bio, Inc. (0002131524) (Filer)
- PRBraveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM Phase 3 enrolling with interim analysis expected in second half of 2027; TRUEHEART-HCM fixed-dose oHCM Phase 2b and NOBLEHEART-HCM Phase 3 in nHCM on track to initiate in first half of 2027 Cash, cash equivalents and investments of $503.5 million; cash runway expected into 2029 SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy
- PRBraveheart Bio to Participate in the Jefferies Global Healthcare Conference in LondonSAN FRANCISCO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (NASDAQ:BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that the Company will participate in the Jefferies Global Healthcare Conference in London, being held November 16-19, 2026. Management will participate in a fireside chat on Wednesday, November 18, 2026, at 1:30 p.m. GMT / 8:30 a.m. ET. Interested parties may access a live webcast by visiting the News & Events section of the Braveheart Bio website at https://ir.braveheart.bio/, with a replay available in a temporary archive foll
- 13D/GSEC Form SCHEDULE 13G filed by Braveheart Bio Inc.SCHEDULE 13G - Braveheart Bio, Inc. (0002131524) (Subject)
- SECBraveheart Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Braveheart Bio, Inc. (0002131524) (Filer)
- PRHengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks Data support a highly simplified dosing regimen, with a majority of patients potentially served by the starting dose HRS/BHB-1893 data across both forms of hypertrophic cardiomyopathy (HCM) and preclinical models suggest potential to address underlying pathophysiology of disease, findings consistent with reverse-remodeling and diastolic benefits Braveheart Bio to host Investor Event and Webcast today at 3:35 p.m. CT (4:35 p.m. ET), including discussion of a planned fixed-dose oHCM study, TR
- 13D/GSEC Form SCHEDULE 13G filed by Braveheart Bio Inc.SCHEDULE 13G - Braveheart Bio, Inc. (0002131524) (Subject)
BRVE FAQ
7 questionsWhat does Braveheart Bio Inc. do?
Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially...What is the latest news on BRVE?
In the last 30 days Quantisnow tracked 10 wire items for BRVE: 4 13D/G filings, 3 SEC filings, 2 press releases and news items and 1 earnings update. The most recent was published on November 16, 2026.Where does BRVE stock trade?
Braveheart Bio Inc. (BRVE) is listed on NASDAQ.What sector and industry is BRVE in?
Braveheart Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Braveheart Bio Inc. go public?
Braveheart Bio Inc. (BRVE) completed its IPO in 2026.What companies are similar to BRVE?
Notable peers in the same industry include MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson). Compare BRVE side-by-side with any of them on Quantisnow.How can I track BRVE on Quantisnow?
Quantisnow aggregates Braveheart Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRVE to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change